Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2025-12-19 00:00:00 ET · period of report 2025-12-17 · accession 0001536368-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-19 | 2025-12-17 | ELVN | Kunkel Lori Anne | Dir | M - OptEx | $1.12 | +16.0K | 30.7K | +108% | +$17.9K |
| D | 2025-12-19 | 2025-12-17 | ELVN | Kunkel Lori Anne | Dir | M - OptEx | $0.00 | -16.0K | 3,741 | -81% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-17 | M | A | 15,958 | $1.12 | 30,712 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2025-12-17 | M | D | 15,958 | $0.00 | 3,741 | D | $1.12 · — to 2030-06-15 | 15,958 Common Stock | (F2) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |